ADC Therapeutics Appoints Dr. Chris Martin as Chief Executive Officer

24-Jun-2015 - Switzerland

ADC Therapeutics Sarl announced the appointment of Dr. Chris Martin as its Chief Executive Officer.

Dr. Martin was co-founder of Spirogen Ltd and its Chief Executive Officer leading up to the sale of Spirogen to MedImmune, the global biologics research and development arm of Astra Zeneca in October 2013 for $440 million in upfront and deferred consideration.  Dr. Martin continued as CEO of Spirogen, and became both a member of Medimmune’s Management Leadership Team and AstraZeneca’s Senior Leaders Group.  Dr. Martin will continue to advise Medimmune as a consultant.

Dr. Martin played an important role in the formation of ADC Therapeutics in 2012, and has served on its board of directors since its founding.   He is a recognised leader in the Antibody Drug Conjugates space, and his leadership of Spirogen led to Spirogen being awarded the Best Scientific Innovation Award in 2014 and Dr Martin being voted by industry peers the winner of the overall ‘Individual Input to the Industry in 2013/2014’ at the World ADC Awards.

Dr. Martin replaces Michael Forer who has served as CEO of the Company since its formation

Other news from the department people

Most read news

More news from our other portals

Fighting cancer: latest developments and advances